ArticleScientific reports2026
UCMSC-derived exosomes ameliorate dry eye disease pathogenesis by modulating neutrophils on Th17/Treg balance.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Dry eye disease (DED) is a chronic ocular surface disorder characterized by Th17/Treg cells imbalance, particularly prevalent among elderly females. Current treatment approaches are evolving from merely providing symptomatic relief to targeting immune dysfunction. Mesenchymal stem cell-derived exosomes (MSC-Exos) have demonstrated the ability to modulate the immune response and promote corneal epithelial cell regeneration in DED. Nonetheless, the precise mechanism through which MSC-Exos exert these effects is not yet fully understood. Consequently, the objective of this study was to explore the mechanisms behind the therapeutic effects of umbilical cord mesenchymal stem cell-derived exosomes (UCMSC-Exos) in a murine model of DED. We discovered that UCMSC-Exos stimulated human corneal epithelial cell lines wound healing in vitro. The topical or systemic administration of UCMSC-Exos significantly altered cytokine expression by neutrophils, leading to a reduction in proinflammatory cytokine expression and an increase in anti-inflammatory cytokine expression. This shift in the cytokine profile reestablished the Treg/Th17 cells balance, resulting in decreased inflammation and alleviation of DED symptoms, with younger mice showing more pronounced benefits. These results highlight the potential of UCMSC-Exos as a therapeutic approach for DED that modulates immune dysregulation and enhances ocular surface repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.